Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Waleed Haso"'
Autor:
Haiying Qin, Sneha Ramakrishna, Sang Nguyen, Thomas J. Fountaine, Anusha Ponduri, Maryalice Stetler-Stevenson, Constance M. Yuan, Waleed Haso, Jack F. Shern, Nirali N. Shah, Terry J. Fry
Publikováno v:
Molecular Therapy: Oncolytics, Vol 11, Iss , Pp 127-137 (2018)
Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the li
Externí odkaz:
https://doaj.org/article/d882270e82e3424288a0765b0e98678d
Autor:
Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic, Rimas J. Orentas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-17 (2017)
Abstract Background Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. To target hematologic
Externí odkaz:
https://doaj.org/article/b97263f6ea1c4fd4ac6a8558dcfabad0
Autor:
Waleed Haso, Terry J. Fry, Nirali N. Shah, Jack F. Shern, Constance M. Yuan, Sneha Ramakrishna, Thomas J. Fountaine, Sang M. Nguyen, Maryalice Stetler-Stevenson, Anusha Ponduri, Haiying Qin
Publikováno v:
Molecular Therapy: Oncolytics, Vol 11, Iss, Pp 127-137 (2018)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the li
Autor:
Ling Zhang, David M. Barrett, Yongshun Lin, Barbara S. Mallon, Poul H Sorensen, Jizhong Zou, Haiying Qin, Terry J. Fry, Htoo Zarni Oo, Shannon L. Maude, Mads Daugaard, Waleed Haso, Monica Cho, Rimas J. Orentas, David T. Teachey, Stephan A. Grupp, Sarah K. Tasian, Gian Luca Negri
Publikováno v:
Blood. 126:629-639
Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 B cell-associated protein have demonstrated potent activity against relapsed/refractory B-lineage acute lymphoblastic leukemia (B-ALL).
Autor:
Jack F. Shern, Meera Murgai, Terry J. Fry, Alec J. Walker, M. Eric Kohler, Rimas J. Orentas, Crystal L. Mackall, Maria Ingaramo, Rosandra N. Kaplan, Kelsey Wanhainen, Adrienne H. Long, Waleed Haso, Jillian P. Smith, George H. Patterson, Vikas R Venkateshwara
Publikováno v:
Nature medicine
Chimeric antigen receptors (CARs) targeting CD19 have mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarely occurred using CARs targeting other antigens. It remains unknown whether the impressive effects o
Autor:
Darong Wu, Andrew Kaiser, Dina Schneider, Ying Xiong, Volker Nӧlle, Boro Dropulic, Sarah Schmitz, Waleed Haso, Rimas J. Orentas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-17 (2017)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. To target hematologic malignanc
Publikováno v:
Oncoimmunology
CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant th
Autor:
Maryalice Stetler-Stevenson, David J. FitzGerald, Waleed Haso, Richard A. Morgan, David M. Barrett, Constance M. Yuan, Dimiter S. Dimitrov, Rimas J. Orentas, Daniel W. Lee, Alan S. Wayne, Ira Pastan, Nirali N. Shah, Crystal L. Mackall
Publikováno v:
Blood. 121(7)
Immune targeting of B-cell malignancies using chimeric antigen receptors (CARs) is a promising new approach, but critical factors impacting CAR efficacy remain unclear. To test the suitability of targeting CD22 on precursor B-cell acute lymphoblastic
Publikováno v:
Blood. 126:4427-4427
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Despite advances in upfront therapy, relapsed and refractory ALL remains a primary cause of cancer-related mortality in children. Immunotherapy using genetically engineered T
Autor:
Crystal L. Mackall, Waleed Haso, Terry J. Fry, Alec J. Walker, Adrienne H. Long, Jillian P. Smith, Rimas J. Orentas
Publikováno v:
Cancer Research. 75:4702-4702
Published reports have demonstrated high response rates of CD19 chimeric antigen receptor (CAR) modified T cells against acute lymphoblastic leukemia. CARs incorporating either CD28 or 4-1BB costimulatory domains mediated significant anti-leukemic ef